RE: April PDF...Posted By Crumbs10 Jun 2019 07:42
Well, feeling all the better for reading that a few times, I have said a few times I felt as if I had missed out on a lot of information, and indeed left it largely to the champion jockeys to explain latest developments better.
The perfect document for newbies to read up on explaining the two platforms (I thought there were now three), the science behind it, progress made and even dosing regimes which I have asked about a few times. I was pretty stumped as to where they could go to get the necessary information, and it is all in a 27 page PDF.
The staffing levels are indeed 23 now, I seem to remember just a couple of years back it was 12, and 12 of those 23 are qualified to Phd level. I do remember Ruck saying when it was discussed that perhaps it was out of need we have increased by so many, which could have been taken a few ways, the way I see it as I did then that with financial restrictions in mind, and Lindys insistance ""she had never seen results like it in 30 years" we have really gone for it, the stages we have reached in the pipeline signify much progress, and is it too simple to suggest that the BOD are very confident of financial resources and where indeed they might be coming from. Certainly not at sub 2p which we were told on here would benefit the company, lol.
So too the first trial coming up in three weeks time SCIB1 in combination with Keytruda, one of my concerns was enrolling 25 patients on time, well that figure is 6 for now, concerns over. And just a very basic description of trial.is in the PDF. Precis was never my greatest attribute, but certainly is to get so much info into 27 very readable pages.
So lets see if we get some news, and for sure see the effect of that article in the FT, avery interesting week ahead.
Sign In
Follow the stocks
